Genenta Science is a pioneering clinical-stage immuno-oncology company that specializes in developing cutting-edge cell-based therapies for solid tumors. Drawing on the power of hematopoietic stem cells, Genenta's innovative platform offers durable and safe treatments that are not restricted to specific tumor types or target antigens. At the heart of Genenta's approach is Temferon™, their lead product candidate.

Temferon™ precisely delivers interferon-alpha to the tumor micro-environment, effectively breaking tumor-induced immune tolerance while minimizing systemic toxicity. These treatments are designed to be one-time monotherapies, but they also have the potential to enhance the efficacy of other approved therapeutics when used in combination. Genenta's proprietary cell-based platform allows for the controlled expression of various cytokines by tumor infiltrating monocytes (TEMs).

This targeted and controlled treatment approach ensures that only the tumor micro-environment is affected, preventing systemic toxicities. Led by a team of highly skilled scientists with extensive experience in cell therapy and drug development, Genenta's research and development pipeline focuses on solid tumors with significant unmet needs. They are currently advancing their autologous oncology products, including Temferon™, through preclinical and clinical assessments.

With a global vision, Genenta Science is revolutionizing cancer treatment by harnessing the potential of cell-based therapies and driving innovation in the field of immuno-oncology